Woofun AI reports that President Trump announced a phased tariff structure for imported generic drugs, maintaining zero rates until August 1, 2026. Following this two-year grace period, tariffs will jump to 100% for one year before increasing to 200%. The administration stated this policy intends to incentivize the relocation of generic drug manufacturing facilities to the United States. Companies failing to establish domestic production capabilities within the specified timeframe will incur these penalties.

Meanwhile, existing 100% tariffs on patented drugs and pharmaceutical ingredients, imposed under Section 232 of the Trade Expansion Act of 1962, remain in effect. These measures seek to pressure pharmaceutical firms into negotiating drug prices and committing to industry reshoring.